Lakefront Biotherapeutics NV (LKFT)
Lakefront Biotherapeutics NV (LKFT) is a healthcare company (biotechnology) based in Belgium. The share price is $34.75, down 0.11% on the day, which values the company at $2.29B. Price as of 17 Nov 2026, 18:20 UTC, from Yahoo Finance.
Key facts
- Share price
- $34.75−0.11% today
- Market value
- $2.29B
- P/E ratio
- 2.5×last 12 months
- Funk Score
- 84/100
- 200-week average
- $32.098% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Lakefront Biotherapeutics NV in more detail
LKFT trades at 2.5× its last twelve months' earnings, -22.3× next year's expected earnings, 2.3× sales. It sits 8% above its 200-week average of $32.09.
Its Funk Score is 84 out of 100 (financial strength 9.4, profitability 7.5, growth 8.3, each out of 10).
In its favour: Strong Piotroski score; More cash than debt. Worth checking: Beneish M-score flags the accounts; Profit is not turning into cash.
1 of the superinvestors tracked here hold LKFT, including David Einhorn (0.4% of the portfolio).
Superinvestors holding LKFT
1 of the investors tracked here report a position in their latest 13F filing.
- David Einhorn Greenlight Capital0.37% of portfolio · $14.5M · Q2 2026
Lakefront Biotherapeutics NV (LKFT): questions and answers
What is LKFT's P/E ratio?
Lakefront Biotherapeutics NV trades at 2.5× its last twelve months' earnings and -22.3× next year's expected earnings.
What is Lakefront Biotherapeutics NV's market cap?
Lakefront Biotherapeutics NV is valued at $2.29B at a share price of $34.75.
Is LKFT above its 200-week moving average?
Yes. LKFT is 8.3% above its 200-week average of $32.09. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Lakefront Biotherapeutics NV growing?
Over the last three fiscal years Lakefront Biotherapeutics NV's revenue grew 66.4% a year.
Does LKFT pay a dividend?
Lakefront Biotherapeutics NV does not currently pay a regular dividend.
Which famous investors own LKFT?
In their latest quarterly filings, David Einhorn (0.4% of the portfolio) hold LKFT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Lakefront Biotherapeutics NV (LKFT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/LKFT
Underlying data: Yahoo Finance; company filings with the SEC.